Abstract:SARS-CoV-2 (severe acute respiratory syndrome coronavirus‐2), a member of the coronavirus family, appeared in 2019 and has caused the largest global public health and economic emergency in recent history, affecting almost all sectors of society. SARS-CoV-2 is a single-stranded positive-sense RNA virus that relies on RNA‐dependent RNA polymerase (RdRp) activity in viral transcription and replication. Due to its high sequence and structural conservation in coronavirus and new SARS-CoV-2 variants, RdRp has been recognized as the key therapeutic target to design novel antiviral strategies. Nucleotide analogs (NAs), such as remdesivir, is the most promising class of RdRp inhibitors to be used in the treatment of COVID-19. However, the presence of exonucleases in SARS-CoV-2 caused a great challenge to NAs; the excision of incorporated NAs will lead to viral resistance to this group of inhibitors. Here, we expressed active RdRp protein in both a eukaryotic expression system of baculovirus-infected insect cells and a prokaryotic expression system of Escherichia coli cells. Nsp7 and nsp8 of the functional RdRp holoenzyme were generated in E. coli . An in vitro RdRp activity assay has been established with a reconstituted nsp12/nsp7/nsp8 complex and biotin-labeled self-priming RNAs, and the activity of the RdRp complex was determined by detecting binding and extension of RNAs. Moreover, to meet the needs of high-throughput drug screening, we developed a fluorometric approach based on dsRNA quantification to assess the catalytic activity of the RdRp complex, which is also suitable for testing in 96-well plates. We demonstrated that the active triphosphate form of remdesivir (RTP) and several reported non-nucleotide analog viral polymerase inhibitors blocked the RdRp in the in vitro RdRp activity assay and high-throughput screening model. This high-throughput screening model has been applied to a custom synthetic chemical and natural product library of thousands of compounds for screening SARS-CoV-2 RdRp inhibitors. Our efficient RdRp inhibitor discovery system provides a powerful platform for the screening, validation, and evaluation of novel antiviral molecules targeting SARS-CoV-2 RdRp, particularly for non-nucleotide antivirals drugs (NNAs).

[Establishment of drug screening assay and pharmacodynamic evaluation method targeting influenza RNA polymerase].

A Parallel Phenotypic Versus Target-Based Screening Strategy For Rna-Dependent Rna Polymerase Inhibitors Of The Influenza A Virus

Establishment of a High-Throughput Assay to Monitor Influenza A Virus RNA Transcription and Replication

Rapid Detection of Influenza A Viruses Using a Real-Time Reverse Transcription Recombinase-Aided Amplification Assay.

Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay

A Cell-Based Assay to Discover Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase.

A cell-based screening system for influenza A viral RNA transcription/replication inhibitors

Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, influenza A and B

Establishment of a rapid ELISPOT assay for influenza virus titration and neutralizing antibody detection

A reporter system for assaying influenza virus RNP functionality based on secreted Gaussia luciferase activity

An Interferon-Beta Promoter Reporter Assay for High Throughput Identification of Compounds Against Multiple RNA Viruses

Prediction and characterization of influenza virus polymerase inhibitors through blind docking and ligand based virtual screening

Identification of Influenza PAN Endonuclease Inhibitors via 3D-QSAR Modeling and Docking-Based Virtual Screening

Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay

Dual-Reporter SARS-CoV-2 Replicon for Screening Viral Polymerase Inhibitors

High-Throughput cell-based immunofluorescence assays against influenza

A practical and rapid screening method for influenza virus neuraminidase inhibitors based on fluorescence detection

Discovery of a potent inhibitor targeting the cap-binding domain of the PB2 subunit of influenza RNA-dependent RNA polymerase

A novel non-radioactive assay for HIV-RT (RdDp) based on pyrosequencing for high-throughput drug screening

An Efficient Modern Strategy to Screen Drug Candidates Targeting RdRp of SARS-CoV-2 With Potentially High Selectivity and Specificity

Identification of influenza virus inhibitors targeting NS1A utilizing fluorescence polarization-based high-throughput assay